source
- Zanubrutinib shows longer overall survival than ibrutinib in real-world relapsed/refractory mantle cell lymphomaA retrospective real‑world analysis examined outcomes of covalent BTK inhibitors in patients with relapsed or refractory mantle cell lymphoma who received treatment in the second or third line. Th…
- INBRX-106 plus pembrolizumab shows higher response rate than pembrolizumab alone in first-line PD-L1-positive head-and-neck cancerThe HexAgon-HN trial evaluated the OX40 agonist INBRX-106 combined with pembrolizumab in patients with treatment-naive, PD-L1‑positive metastatic or unresectable head‑and‑neck squamous cell carcino…onclive · 4mo agoPositive readoutPositive